Desflurane is a general anesthetic indicated for induction and/or maintenance of anesthesia in adults, among other approved uses. It is available as inhalation solution. MedsAcross supplies Desflurane for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
SUPRANE, a general anesthetic, is an inhalation agent indicated: • for induction and/or maintenance of anesthesia in adults. • for maintenance of anesthesia in pediatric patients following induction with agents other than SUPRANE and intubation.
Source: US FDA prescribing information
Only persons trained in the administration of general anesthesia should administer SUPRANE. Only a vaporizer specifically designed and designated for use with desflurane should be utilized for its administration. Facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment, and circulatory resuscitation must be immediately available. SUPRANE is administered by inhalation. The administration of general anesthesia must be individualized based on the patient’s response. Hypotension and respiratory depression increase as anesthesia with SUPRANE is deepened. The minimum alveolar concentration (MAC) of SUPRANE decreases with increasing patient age. The MAC for SUPRANE is also reduced by concomitant N 2 O administration. The dose should be adjusted accordingly.
Source: US FDA prescribing information
The use of SUPRANE is contraindicated in the following conditions: • Known or suspected genetic susceptibility to malignant hyperthermia. • Patients in whom general anesthesia is contraindicated. • Induction of anesthesia in pediatric patients. • Patients with known sensitivity to SUPRANE or to other halogenated agents. • Patients with a history of moderate to severe hepatic dysfunction following anesthesia with SUPRANE or other halogenated agents and not otherwise explained. • Patients with known or suspected genetic susceptibility to malignant hyperthermia. • Patients in whom general anesthesia is contraindicated. • Induction of anesthesia in pediatric patients.
Source: US FDA prescribing information
• Malignant Hyperthermia: Malignant hyperthermia may occur, especially in individuals with known or suspected susceptibility based on genetic factors or family history. Discontinue triggering agents, administer intravenous dantrolene sodium, and apply supportive therapies. • Perioperative Hyperkalemia: Perioperative hyperkalemia may occur. Patients with latent or overt neuromuscular disease, particularly with Duchenne muscular dystrophy, appear to be most vulnerable. Early, aggressive intervention is recommended. • Respiratory Adverse Reactions in Pediatric Patients: - Not approved for maintenance of anesthesia in non-intubated children due to an increased incidence of respiratory adverse reactions. Monitor and treat accordingly. - May cause airway narrowing and increased airway resistance in children with asthma or a history of recent upper airway infection.
Source: US FDA prescribing information
Most common adverse reactions (incidence> 10%) are coughing, breath holding, apnea, nausea, vomiting.
Source: US FDA prescribing information
No clinically significant adverse interactions with commonly used preanesthetic drugs, or drugs used during anesthesia (muscle relaxants, intravenous agents, and local anesthetic agents) were reported in clinical trials. The effect of SUPRANE on the disposition of other drugs has not been determined. Similar to isoflurane, SUPRANE does not predispose to premature ventricular arrhythmias in the presence of exogenously infused epinephrine in swine. • Concomitant use of N 2 O, benzodiazepines and/or opioids reduces the MAC of SUPRANE. Adjust dose accordingly. • SUPRANE decreases the doses of neuromuscular blocking agents required. Adjust dose accordingly.
Source: US FDA prescribing information
Store at room temperature, 15°-30°C (59°-86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
2 presentations of Desflurane, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Suprane 240 mL/240 mL inhalation solutionInhalation | Baxter Healthcare | US FDA | Available on request |
| Desflurane 240 mL/240 mL inhalation solutionInhalationGeneric name | — | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 18 September 1992 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Desflurane in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 2 presentations of Desflurane and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Desflurane, including Suprane.
Yes. The US FDA first approved Desflurane on 18 September 1992, according to Drugs@FDA.
No listed presentation of Desflurane is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Desflurane is classified under ATC code N01AB07 (Desflurane).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.